Market closedADR
XTL Biopharmaceuticals/$XTLB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Ticker
$XTLB
Sector
Trading on
Industry
Biotechnology
Headquarters
Ramat Gan, Israel
Employees
5
Website
XTLB Metrics
BasicAdvanced
$12M
-
-$0.00
1.05
-
Price and volume
Market cap
$12M
Beta
1.05
52-week high
$1.54
52-week low
$1.19
Financial strength
Current ratio
0.805
Quick ratio
0.754
Interest coverage (TTM)
-42.16%
Management effectiveness
Return on assets (TTM)
-16.33%
Return on equity (TTM)
-25.70%
Valuation
Price to revenue (TTM)
16,025.641
Price to book
7.4
Price to tangible book (TTM)
-31.15
Growth
Earnings per share change (TTM)
-49.11%
3-year earnings per share growth (CAGR)
-26.20%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for XTL Biopharmaceuticals stock?
XTL Biopharmaceuticals (XTLB) has a market cap of $12M as of March 09, 2025.
What is the P/E ratio for XTL Biopharmaceuticals stock?
The price to earnings (P/E) ratio for XTL Biopharmaceuticals (XTLB) stock is 0 as of March 09, 2025.
Does XTL Biopharmaceuticals stock pay dividends?
No, XTL Biopharmaceuticals (XTLB) stock does not pay dividends to its shareholders as of March 09, 2025.
When is the next XTL Biopharmaceuticals dividend payment date?
XTL Biopharmaceuticals (XTLB) stock does not pay dividends to its shareholders.
What is the beta indicator for XTL Biopharmaceuticals?
XTL Biopharmaceuticals (XTLB) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.